These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 21729110)

  • 21. Neuronal nicotinic acetylcholine receptors - targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease.
    Haydar SN; Dunlop J
    Curr Top Med Chem; 2010; 10(2):144-52. PubMed ID: 20166959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. α7 Nicotinic receptor modulators for cognitive deficits in schizophrenia and Alzheimer's disease.
    Geerts H
    Expert Opin Investig Drugs; 2012 Jan; 21(1):59-65. PubMed ID: 22047592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of α7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: implications for therapy of cognitive dysfunction in schizophrenia.
    McLean SL; Grayson B; Idris NF; Lesage AS; Pemberton DJ; Mackie C; Neill JC
    Eur Neuropsychopharmacol; 2011 Apr; 21(4):333-43. PubMed ID: 20630711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations.
    Williams DK; Wang J; Papke RL
    Biochem Pharmacol; 2011 Oct; 82(8):915-30. PubMed ID: 21575610
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential Use of Nicotinic Receptor Agonists for the Treatment of Chemotherapy-Induced Cognitive Deficits.
    Philpot RM
    Neurochem Res; 2015 Oct; 40(10):2018-31. PubMed ID: 25652578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Procognitive effects of varenicline in the animal model of schizophrenia depend on α4β2- and α 7-nicotinic acetylcholine receptors.
    Potasiewicz A; Golebiowska J; Popik P; Nikiforuk A
    J Psychopharmacol; 2018 Dec; 33(1):269881118812097. PubMed ID: 30501536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alpha-7 nicotinic acetylcholine receptor agonists selectively activate limbic regions of the rat forebrain: an effect similar to antipsychotics.
    Hansen HH; Timmermann DB; Peters D; Walters C; Damaj MI; Mikkelsen JD
    J Neurosci Res; 2007 Jun; 85(8):1810-8. PubMed ID: 17455307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nicotinic receptors and lurasidone-mediated reversal of phencyclidine-induced deficit in novel object recognition.
    Miyauchi M; Neugebauer NM; Oyamada Y; Meltzer HY
    Behav Brain Res; 2016 Mar; 301():204-12. PubMed ID: 26519556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia.
    Barak S; Arad M; De Levie A; Black MD; Griebel G; Weiner I
    Neuropsychopharmacology; 2009 Jun; 34(7):1753-63. PubMed ID: 19158670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. α7 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: Update on animal and clinical studies and strategies for the future.
    Terry AV; Callahan PM
    Neuropharmacology; 2020 Jun; 170():108053. PubMed ID: 32188568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia.
    Zhang XY; Liu L; Liu S; Hong X; Chen DC; Xiu MH; Yang FD; Zhang Z; Zhang X; Kosten TA; Kosten TR
    Am J Psychiatry; 2012 Sep; 169(9):974-81. PubMed ID: 22952075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective alpha7 nicotinic acetylcholine receptor ligands.
    Mazurov A; Hauser T; Miller CH
    Curr Med Chem; 2006; 13(13):1567-84. PubMed ID: 16787204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting alpha7 nicotinic acetylcholine receptors in the treatment of schizophrenia.
    Hajós M; Rogers BN
    Curr Pharm Des; 2010; 16(5):538-54. PubMed ID: 19909231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Evolving Therapeutic Rationale for Targeting the α
    Deutsch SI; Burket JA
    Curr Top Behav Neurosci; 2020; 45():167-208. PubMed ID: 32468495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors reverse ketamine-induced schizophrenia-like deficits in rats.
    Nikiforuk A; Kos T; Hołuj M; Potasiewicz A; Popik P
    Neuropharmacology; 2016 Feb; 101():389-400. PubMed ID: 26232639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship.
    Wishka DG; Walker DP; Yates KM; Reitz SC; Jia S; Myers JK; Olson KL; Jacobsen EJ; Wolfe ML; Groppi VE; Hanchar AJ; Thornburgh BA; Cortes-Burgos LA; Wong EH; Staton BA; Raub TJ; Higdon NR; Wall TM; Hurst RS; Walters RR; Hoffmann WE; Hajos M; Franklin S; Carey G; Gold LH; Cook KK; Sands SB; Zhao SX; Soglia JR; Kalgutkar AS; Arneric SP; Rogers BN
    J Med Chem; 2006 Jul; 49(14):4425-36. PubMed ID: 16821801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Positive allosteric modulators of α7* or β2* nicotinic acetylcholine receptors trigger different kinase pathways in mitochondria.
    Uspenska K; Lykhmus O; Arias HR; Pons S; Maskos U; Komisarenko S; Skok M
    Int J Biochem Cell Biol; 2018 Jun; 99():226-235. PubMed ID: 29704624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repeated administration of alpha7 nicotinic acetylcholine receptor (nAChR) agonists, but not positive allosteric modulators, increases alpha7 nAChR levels in the brain.
    Christensen DZ; Mikkelsen JD; Hansen HH; Thomsen MS
    J Neurochem; 2010 Aug; 114(4):1205-16. PubMed ID: 20533993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies.
    Lewis AS; van Schalkwyk GI; Bloch MH
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Apr; 75():45-53. PubMed ID: 28065843
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological Characterization of the Novel and Selective
    Wang X; Daley C; Gakhar V; Lange HS; Vardigan JD; Pearson M; Zhou X; Warren L; Miller CO; Belden M; Harvey AJ; Grishin AA; Coles CJ; O'Connor SM; Thomson F; Duffy JL; Bell IM; Uslaner JM
    J Pharmacol Exp Ther; 2020 May; 373(2):311-324. PubMed ID: 32094294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.